Navigation Links
Orexigen Therapeutics to Present Data on Contrave Impact on,Visceral Fat and Insulin Resistance at American Diabetes,Association 67th Scientific Sessions in Chicago June 23

SAN DIEGO, June 21, 2007 /PRNewswire-FirstCall/ -- Orexigen(TM) Therapeutics, Inc. , a biopharmaceutical company focused on the treatment of central nervous system disorders with an initial focus on obesity, today announced that the Company will present data about its lead obesity product candidate Contrave(TM) and its effect on markers of cardiovascular disease (visceral fat, serum cholesterol, and triglycerides) and insulin-resistance. The findings come from additional analyses of the Phase IIb multi-center clinical trial of Contrave. The data will be presented on Saturday, June 23rd, 6:00-7:15 pm and Monday, June 25th, 2007 at the 67th Annual Scientific Sessions of the American Diabetes Association (ADA) in Chicago, IL. Contrave data can be found in category 20B, poster number 45LB entitled, "Weight Loss with Bupropion and Naltrexone Improves Markers of Insulin-Resistance."

Contrave is a proprietary fixed dose combination of bupropion SR (sustained release) and Orexigen's novel formulation of naltrexone SR in a single tri-layer tablet. In a Phase IIb multi-center clinical trial, Contrave demonstrated statistically significant weight loss at 24 weeks compared to bupropion SR alone, naltrexone IR (immediate release) alone, and placebo. Contrave is now being studied in two separate multi-center Phase III studies, one of which is designed to further assess its safety and efficacy in obese subjects with Type II diabetes.

About Orexigen Therapeutics

Orexigen(TM) Therapeutics, Inc. is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of central nervous system disorders, with an initial focus on obesity. Orexigen's lead combination product candidates targeted for obesity are Contrave(TM), which is in Phase III clinical trials, and Empatic(TM) (formerly Excalia(TM)), which is in a Phase IIb clinical trial. Both product candidates take ad
'"/>




Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
9. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
10. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
11. Barrier Therapeutics Announces Liarozole Phase 2/3 Study Results in Lamellar Ichthyosis
Post Your Comments:
(Date:7/27/2015)... -- EnzymeBioSystems (OTC BB: ENZB - News) announces that a ... the Company,s lead pharmaceutical product. EnzymeBioSystems plans to seek ... prevention of breast cancer. "We are pleased ... has been completed," stated Gary Rojewski , CEO ... will allow us to move forward in beginning to ...
(Date:7/27/2015)... , July 20, 2015 ... the addition of the "Global Pressure Relief Devices ... The Global Pressure Relief Devices market to grow at ... The report, Global Pressure Relief Devices Market 2015-2019, has ... inputs from industry experts. The report covers the Americas, ...
(Date:7/27/2015)... DUBLIN , July 20, 2015 ... ) has announced the addition of the ... offering. Afrezza,s discounted pricing is in ... strategy is critical to the product,s commercial appeal. ... to prevent Afrezza from gaining a sizeable share ...
Breaking Medicine Technology:Amooranin Preclinical Sample Batch Completed 2Global Pressure Relief Devices Market 2015-2019 with ArjoHuntleigh, Hill-Rom, Paramount Bed Holdings & Stryker Dominating 2Cardiometabolic Drug News Issue - Afrezza Aggressive Pricing Strategy View Playing Out 2Cardiometabolic Drug News Issue - Afrezza Aggressive Pricing Strategy View Playing Out 3
... studies; Data to be presented at AACR - ... and development company Esperance Pharmaceuticals today presented positive ... support the initiation of clinical trials in cancer. ... Cationic Lytic Peptide (CLYP(TM)) platform technology. EP-100 is ...
... Israel, April 21 NanoVibronix, a medical ... ultrasound waves,announced that its novel device has ... of wound healing. PainShield is the first ... for therapeutic,treatment of wounds. The innovative PainShield ...
Cached Medicine Technology:First Candidate from Esperance's Targeted Anti-cancer Platform, EP-100, Establishes Preclinical Proof of Concept 2First Candidate from Esperance's Targeted Anti-cancer Platform, EP-100, Establishes Preclinical Proof of Concept 3NanoVibronix Receives Wound Healing Indications in Europe for its PainShield(TM) Device 2
(Date:7/27/2015)... ... ... Los Angeles , Dr. Poneh Ghasri, is now offering a teeth whitening special just in ... can help brighten up a person’s look, help him or her shed the winter blues ... to get a whiter smile. Dr. Ghasri, Los Angeles dental treatment expert, offers ...
(Date:7/27/2015)... ... July 27, 2015 , ... Sher Fertility Institute, ... treatment, has added a veteran physician to their clinical team in Las Vegas. , ... of the most experienced, most successful Reproductive Endocrinology teams in the region. , Combined ...
(Date:7/27/2015)... MA (PRWEB) , ... July 27, 2015 , ... ... Social Security Disability Insurance (SSDI) and Medicare, has welcomed Jon Cogswell as the ... working in contact center environments and has played a significant role in the ...
(Date:7/27/2015)... ... July 27, 2015 , ... Continuing their ongoing community improvement ... greater San Antonio area, is launching a joint charity effort with the South ... Big Sister Organization of South Texas is committed to serving underprivileged and poverty-stricken ...
(Date:7/27/2015)... ... July 27, 2015 , ... Rountree ... Savannah area, is launching a new charity drive to support Next Generation, a ... Medical Center in Savannah, Georgia. , Next Generation workers are dedicated to improving ...
Breaking Medicine News(10 mins):Health News:Los Angeles Cosmetic Dentist, Dr. Poneh Ghasri, Is Now Offering a Teeth Whitening Special Just in Time for Summer 2Health News:Dr. Mark Severino Joins Dr. Geoffrey Sher at Sher Fertility Las Vegas- Sher Fertility is National Network of Fertility Clinics Known for Exceptional Patient Care 2Health News:Dr. Mark Severino Joins Dr. Geoffrey Sher at Sher Fertility Las Vegas- Sher Fertility is National Network of Fertility Clinics Known for Exceptional Patient Care 3Health News:The Advocator Group, LLC Announces Jonathan Cogswell as Vice President of Client Services 2Health News:The Advocator Group, LLC Announces Jonathan Cogswell as Vice President of Client Services 3Health News:Shacklett Insurance Team Joins Local Chapter of Big Brother Big Sister Organization to Initiate Joint Charity Effort to Benefit Children in San Antonio 2Health News:Shacklett Insurance Team Joins Local Chapter of Big Brother Big Sister Organization to Initiate Joint Charity Effort to Benefit Children in San Antonio 3Health News:Rountree Brady Announces Charity Effort to Support Children’s Services at the Memorial University Medical Center Hospital 2Health News:Rountree Brady Announces Charity Effort to Support Children’s Services at the Memorial University Medical Center Hospital 3
... can safely turn to a minimally invasive operation for ... Johns Hopkins University physicians., ,Endoscopic therapy is ... says Anthony N. Kalloo, MD, director of GI endoscopy ... appeared in the July 2000 issue of Gastrointestinal Endoscopy. ...
... Measurement of serum progesterone levels may be helpful ... strong clinical signs are at low risk of ... August issue of the Annals of Emergency Medicine. ... first-trimester patients ,who presented to an emergency department ...
... often ,have severe neurologic and developmental disabilities, researchers report ... of Medicine.The EPICure Study Group identified 308 ,children born ... in the UK and Ireland. Of these, 283 were ... on the Mental and Psychomotor Development Indexes compared with ...
... by the FDA in ,the United States on July 31, ... often part of hirsutism. , , ,It may be ... considered serious enough to warrant tweezing, waxing, or shaving ... is actually not a brand new drug, but ,rather a ...
... regenerated using stem cells from blood -- an important discovery ... liver transplants using bone marrow. This adds to a growing ... because they can produce a variety of different kinds of ... transplants. , , ,"The liver is an incredibly regenerative organ ...
... UT Southwestern in Dallas soon report that amphetamines may speed ... the function., , ,This study was done on patients who had ... blood and oxygen to the brain., , ,Amphetamines were given to ... told that while they don't know for sure until the results ...
Cached Medicine News:
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: